MA56032A - Composés, compositions et procédés d'utilisation - Google Patents

Composés, compositions et procédés d'utilisation

Info

Publication number
MA56032A
MA56032A MA056032A MA56032A MA56032A MA 56032 A MA56032 A MA 56032A MA 056032 A MA056032 A MA 056032A MA 56032 A MA56032 A MA 56032A MA 56032 A MA56032 A MA 56032A
Authority
MA
Morocco
Prior art keywords
compositions
compounds
methods
Prior art date
Application number
MA056032A
Other languages
English (en)
Inventor
Allen Taylor Hopper
Daniel La
Steven Mischke
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA56032A publication Critical patent/MA56032A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA056032A 2019-05-24 2020-05-24 Composés, compositions et procédés d'utilisation MA56032A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962852565P 2019-05-24 2019-05-24

Publications (1)

Publication Number Publication Date
MA56032A true MA56032A (fr) 2022-04-06

Family

ID=71078654

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056032A MA56032A (fr) 2019-05-24 2020-05-24 Composés, compositions et procédés d'utilisation

Country Status (7)

Country Link
US (1) US20220332699A1 (fr)
EP (1) EP3976186A1 (fr)
JP (2) JP7687964B2 (fr)
AR (1) AR119010A1 (fr)
MA (1) MA56032A (fr)
TW (2) TW202523658A (fr)
WO (1) WO2020243027A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (fr) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Steroides neuroactifs, compositions et leurs utilisations
EP2806877B2 (fr) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Formulations de stéroïdes neuroactifs comprenant un complexe d'allopregnanolone et de sulfobutyl ether beta-cyclodextrine
CA2882708A1 (fr) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Procedes de traitement de l'epilepsie ou d'un etat de mal epileptique
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (fr) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions et procédés pour traiter des troubles du snc
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
EP3504189A1 (fr) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
US20240189312A1 (en) * 2022-12-02 2024-06-13 Morehouse School Of Medicine Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20100152160A1 (en) * 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
EP2982666B1 (fr) * 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique
MX2022003845A (es) * 2019-09-30 2022-06-22 Actinogen Medical Ltd Tratamientos cognitivos medicinales.

Also Published As

Publication number Publication date
TWI855081B (zh) 2024-09-11
AR119010A1 (es) 2021-11-17
US20220332699A1 (en) 2022-10-20
WO2020243027A1 (fr) 2020-12-03
TW202110824A (zh) 2021-03-16
JP2022533436A (ja) 2022-07-22
TW202523658A (zh) 2025-06-16
JP7687964B2 (ja) 2025-06-03
EP3976186A1 (fr) 2022-04-06
JP2025090698A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
MA56032A (fr) Composés, compositions et procédés d'utilisation
EP3768267A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3962296A4 (fr) Compositions de cannabinoïdes et procédés d'utilisation
EP3923935A4 (fr) Composés, compositions et procédés
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3790596A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3713560A4 (fr) Composés bêta-hydroxybutyrate non racémiques et compositions enrichies en l'énantiomère r, et leurs procédés d'utilisation
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
EP3806906A4 (fr) Nouveaux composés cétogènes, compositions, procédés et utilisation de ceux-ci
MA54946A (fr) Procédés et composés
MA54959A (fr) Composés, compositions et procédés
EP3801551A4 (fr) Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
EP3316894A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
MA55532A (fr) Composés de neuréguline-4 et procédés d'utilisation
EP3941459A4 (fr) Composés de quinoléine et de quinazoline et leurs procédés d'utilisation
EP3886854A4 (fr) Composés pyrrole et pyrazole et leurs procédés d'utilisation
EP3790552A4 (fr) Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
MA54148A (fr) Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
EP3781163A4 (fr) Compositions infusées avec des composés de nicotine et leurs procédés d'utilisation